SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 26/06/2024 am IST			5-day change	1st Jan Change
2.94 ^USD	-0.68%		+13.95%	-57.24%

20/06	SAB Biotherapeutics, Inc. has Changed its Name to SAB BIO	CI
07/06	Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target	MT

SAB BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)

January 07, 2022 at 03:34 am IST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 31, 2021, Charles H. Randall, Chief Strategy Officer of SAB Biotherapeutics, Inc. (the "Company"), resigned. The Company and Mr. Randall are finalizing the terms of a release and severance under his employment agreement.

Latest news about SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. has Changed its Name to SAB BIO	20/06	CI
Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target	07/06	MT
SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer	31/05	CI
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics	21/05	CI
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors	06/05	CI
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	16/04	CI
HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating	02/04	MT
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline	25/03	MT
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	25/03	CI
SAB Biotherapeutics Executive Chairman Samuel Reich Adds CEO Role	03/02	MT
SAB Biotherapeutics, Inc. Announces CEO Changes	02/02	CI
SAB Biotherapeutics Regains Nasdaq Compliance	24/01	MT
SAB Biotherapeutics to Effect 1-for-10 Reverse Stock Split; Shares Fall After-Hours	03/01	MT
SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142	29/11	CI
SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors	20/11	CI
HC Wainwright Trims SAB Biotherapeutics' Price Target to $1 From $2, Keeps Buy Rating	15/11	MT
SAB Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
SAB Biotherapeutics, Inc. Appoints Michael G. King Jr. as Chief Financial Officer	25/23/25	CI
North American Morning Briefing : Investors Await -2-	06/23/06	DJ
Ladenburg Thalmann Downgrades SAB Biotherapeutics to Neutral From Buy	05/23/05	MT
SAB Biotherapeutics Appoints Andrew Moin to Board of Directors	05/23/05	CI
Sab Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors	05/23/05	CI
SAB Biotherapeutics, Inc. announced that it expects to receive $130 million in funding	02/23/02	CI

Chart SAB Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.

Sector

Biotechnology & Medical Research

Calendar

27/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.94 USD

Average target price

13 USD

Spread / Average Target

+342.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAB BIOTHERAPEUTICS, INC.	-57.24%	2.71Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	12TCr
REGENERON PHARMACEUTICALS, INC.	+21.96%	12TCr
ARGENX SE	+23.73%	2.7TCr
BIONTECH SE	-20.05%	2.04TCr
BEIGENE, LTD.	-16.28%	1.59TCr
GENMAB A/S	-16.52%	1.64TCr
WUXI APPTEC CO., LTD.	-44.35%	1.56TCr
SAREPTA THERAPEUTICS, INC.	+63.91%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+2.52%	1.36TCr

Bio Therapeutic Drugs